Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>/= 18 years of age~* Diabetes mellitus, Type 2~* Moderately impaired kidney function~* Drug naive or up to 2 antihyperglycemic medications at stable dose for over 1 month at screening~* BMI 25-35~Exclusion Criteria:~* Current or previous treatment with a thiazolidinedione~* Current or previous treatment with insulin~* Treatment with fibrates \<3 months prior to screening~* History of renal disease other than diabetic nephropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aleglitazar (Type: EXPERIMENTAL): None
- pioglitazone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).